samedan logo
 
 
spacer
home > ict > Autumn 2010
PUBLICATIONS

International Clinical Trials

ict
Autumn 2010
   
Text
PDF
bullet
REGULATORY

Complicated and rigorous, the safety management process can often become an ardous but necessary burden for trial coordinators to carry. Miriam Marotti at Prism Ideas shows how pharmacovigilance providers can lighten the load.

 

 
view
download pdf
Risk management has become a task for all levels of business operations since the publication of ICHQ9 Quality Risk Management.Andreas Grund of GCP Service International explains how to reassess approaches to risk, ultimately treating them as an opportunity to add value.  
view
download pdf
bullet
TRIAL MANAGEMENT
Paediatric clinical trials pose ethical, regulatory and practical issues,which have led to low interest from pharma companies. Philippa Smit-Marshall at PharmaNet explains how these hurdles can be overcome in sites around the world.  
view
download pdf
Cyril Clarke at ICON Development Solutions shows how the expensive, largely unsuccessful process of researching a new drug can be offset by a shift in the proof-of-concept stage, which aims to minimise the impact of failed Phase III trials.  
view
download pdf
The drug approval process in the EU is faster and more transparent – something which US firms would do well to take advantage of. Angus G Cameron at Pharmarama Inc discusses the details of sourcing EU-approved drugs for bioequivalence studies.  
view
download pdf
bullet
Regional trials
With its large population and highly developed economy, Japan should be a prime location for clinical trials.However, there are a number of obstacles holding the location back, explains Jeremy Buchman at BBK Worldwide.  
view
download pdf
Dana L Niedzielska and Mikhail Kandalov at PPD introduce Russia’s clinical research sector and the rapid progress that has been made in the country’s various regions over the last 15 years, and discuss how further development can be pursued.  
view
download pdf
In a continuation of the eastern European focus,David Passov at ClinStar delves into the financial benefits of choosing to conduct trials in the region, giving examples of how time, and therefore money, can be saved for both sponsor and CRO.  
view
download pdf
The third in the series, Oleg Mediannikov and Denis Pyak at Tetrial CRO focus on the Russia’s response to clinical trials for generic drugs, and point out the regulatory issues that must be overcome by CROs, while also charting the potential for development in the region.  
view
download pdf
Bindhya Cariappa of ClinTec International turns to India and the Gulf region to look at the high prevalence of diabetes in these locations, and how they offer a valuable opportunity for clinical researchers, in terms of both the variety and naivety of the population.  
view
download pdf
eCLINICAL, DATA MANAGEMENT & STATISTICAL ANALYSIS
Nick Halkitis, Liz Moench and Duncan Shaw at MediciGlobal reveal a host of options for online patient recruitment and point out that, despite rapid development in the digital world, clinical researchers in the real world are still playing catch-up.  
view
download pdf
Hard copy records are still firmly ingrained in today’s clinical trials administration systems, despite the clear advantages of electronic archiving has to offer. Dimitri Stamatiadis at Merck Serono highlights these benefits and assesses how change can come about.  
view
download pdf
Scott Dixon of Phase Forward Inc shows how web-based ePRO can improve the information provided by patient reported outcomes, offering a more accessible user experience as well as providing an element of control that appeals to patients.  
view
download pdf
bullet
THERAPEUTICS
Radiography is currently entrenched as the standard FDA-approved method of clinical assessment for rheumatoid arthritis. However,magnetic resonance imaging can be shown to be superior on many counts, as Harris A Ahmad at BioClinica, Inc illustrates.  
view
download pdf
The market for autoimmune disease therapies in the developed world is undergoing rapid growth and companies’ sales are increasing accordingly. However, James Wentworth at Datamonitor believes less developed economies may also harbour similar untapped potential.  
view
download pdf
bullet
Drug delivery & Therapeutics
Berwyn Clarke and Aino Telaranta-Keerie at Lab21 chart the progress of recent developments in cancer therapeutics; revealing successful avenues for molecular diagnostics in oncology and giving examples of molecules that have not lived up to their potential.  
view
download pdf
Chris Moriarty at Randox Pharma Services explains how a three-pronged offensive can often be the best solution when choosing a diagnostic partner, and provides a breakdown of what factors to consider in the selection process.  
view
download pdf
bullet
Labs & Logistics

Geraint Thomas at Laminar Medica explains how Class 6, Division 6.2 infectious biological substances can present a serious challenge for logistics managers, and offers insight into clinical trial packaging technologies that fulfil the regulation’s requirements.

 
view
download pdf
Editor Graham Hughes looks at The Professional Guinea Pig by Roberto Abadie, which charts the experiences of those who partake in clinical trials for a living.The book examines the patients’ views on the risks they assumed by participating on a regular basis.  
view
download pdf
   
spacer
Edited by
Dr Graham Hughes
Consultant in
Pharmaceutical
Development

Published quarterly in
February, May,
August, and November

News and Press Releases

Digital Manufacturing is a top priority for Life Sciences according to Zenith survey

Zenith Technologies, a world leader in delivering GMP manufacturing software solutions to the life sciences industry, recently conducted an industry survey that suggests the digital manufacturing is a top priority.
More info >>

White Papers

Recommendations for Implementing Assessment Criteria Guidelines in Lymphoma and Chronic Lymphocytic Leukemia Clinical Trials

Perceptive Informatics

Standardized assessment criteria are becoming increasingly important in obtaining valid outcomes in oncology clinical trials. While standardized criteria encourage a more uniform approach to assessing clinical trial data, they are often subject to the interpretation of the user. These differences in interpretation, while seemingly minor, can have a major impact on assessments. The most commonly used standardized criteria for lymphoma have been no exception. Differences such as minimum new lesion size, lymph node normalization size requirements, inclusion of extranodal lesions and assessment of organomegaly can have a profound effect on overall response. Additionally, heightened scrutiny of the assessment criteria used in a given protocol can lead to questions about a drug’s efficacy if not applied correctly according to regulators’ interpretation.
More info >>

Industry Events

PDA Europe Annual Meeting 2019

24 June 2019, Hilton Amsterdam

Featuring updates from international regulatory agencies as well as industry, this promises to become another highlight in the 2019 event calendar and is a meeting not to be missed!
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement